Brooklyn Immunotherapeutics Inc
NASDAQ:BTX
Relative Value
There is not enough data to reliably calculate the relative value of BTX.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
BTX Competitors Multiples
Brooklyn Immunotherapeutics Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
B
|
Brooklyn Immunotherapeutics Inc
NASDAQ:BTX
|
549.9k USD | 0.1 | -0.1 | -0.2 | -0.1 | |
US |
Abbvie Inc
NYSE:ABBV
|
284B USD | 5.2 | 58.9 | 12.8 | 19.5 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
149.1B USD | 5.3 | 22.2 | 16.5 | 24.7 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.1B USD | 10.4 | 28.5 | 22.8 | 23.9 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
102.6B USD | 7.8 | 25.9 | 17.4 | 19.1 | ||
AU |
CSL Ltd
ASX:CSL
|
133B AUD | 6.2 | 35.4 | 21.4 | 26.6 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.4B USD | 3 | 168.2 | 6.7 | 8.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
48B USD | 7 | -10.2 | -11 | -9.4 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.1B USD | 3.2 | 26.6 | 13.7 | 17.1 | ||
KR |
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 | 72.5 | 44.4 | 61.1 |